|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
GB8918616D0
(en)
|
1989-08-15 |
1989-09-27 |
Univ Glasgow |
Herpes simplex virus type 1 mutant
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
GB9415319D0
(en)
|
1994-07-29 |
1994-09-21 |
Medical Res Council |
HSV viral vector
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
EP1002119A1
(en)
|
1997-07-31 |
2000-05-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeted hsv vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
PL369371A1
(en)
|
2002-01-03 |
2005-04-18 |
Schering Aktiengesellschaft |
New methods for diagnosis and treatment of tumours
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
WO2005113595A2
(en)
|
2004-05-19 |
2005-12-01 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
WO2007042289A2
(en)
|
2005-10-11 |
2007-04-19 |
Ablynx N.V. |
Nanobodies™ and polypeptides against egfr and igf-ir
|
|
US20090304657A1
(en)
|
2006-05-03 |
2009-12-10 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Chimeric t cell receptors and related materials and methods of use
|
|
PL2155788T3
(pl)
|
2007-04-03 |
2013-02-28 |
Amgen Res Munich Gmbh |
Swoiste międzygatunkowe bispecyficzne czynniki wiążące
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
WO2011097456A2
(en)
|
2010-02-05 |
2011-08-11 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
|
EP2694640B1
(en)
|
2011-04-08 |
2017-10-18 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
EP2760891B1
(en)
|
2011-09-26 |
2018-11-07 |
JN Biosciences LLC |
Hybrid constant regions
|
|
US20150218280A1
(en)
|
2012-08-10 |
2015-08-06 |
University Of Southern California |
CD20 scFv-ELPs METHODS AND THERAPEUTICS
|
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
|
WO2014146672A1
(en)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2014172584A1
(en)
|
2013-04-17 |
2014-10-23 |
Baylor College Of Medicine |
IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
|
|
CN110511960B
(zh)
|
2013-07-15 |
2023-05-23 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
EP3177314B1
(en)
|
2014-08-04 |
2020-10-07 |
Fred Hutchinson Cancer Research Center |
T cell immunotherapy specific for wt-1
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
US10577417B2
(en)
*
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
AU2015380397B2
(en)
|
2015-01-31 |
2021-10-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
HK1253507A1
(zh)
|
2015-05-18 |
2019-06-21 |
Eureka Therapeutics, Inc. |
抗 ror1 抗体
|
|
US11667691B2
(en)
*
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
ES2987986T3
(es)
|
2016-06-10 |
2024-11-18 |
Gadeta B V |
Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
|
|
PL3896091T3
(pl)
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
IL310865A
(en)
|
2016-10-17 |
2024-04-01 |
Pfizer |
Antibodies against EDB and antibody-drug conjugates
|
|
US11654158B2
(en)
|
2016-11-17 |
2023-05-23 |
2Seventy Bio, Inc. |
TGFBeta signal convertor
|
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
|
US20190375815A1
(en)
*
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
US11236145B2
(en)
|
2017-03-23 |
2022-02-01 |
Immatics Biotechnologies Gmbh |
T cell receptors and immune therapy using the same against PRAME positive cancers
|
|
EP3600357A4
(en)
|
2017-03-31 |
2021-01-06 |
The Board of Trustees of the Leland Stanford Junior University |
METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
|
|
AU2018289428B2
(en)
|
2017-06-21 |
2024-06-27 |
The General Hospital Corporation |
Methods and compositions for chimeric antigen receptor targeting cancer cells
|
|
JP7391015B2
(ja)
|
2017-09-29 |
2023-12-04 |
アメリカ合衆国 |
Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
|
|
GB201717578D0
(en)
|
2017-10-26 |
2017-12-13 |
Univ College Cardiff Consultants Ltd |
Novel T-cell receptor
|
|
CA3088161A1
(en)
|
2018-01-11 |
2019-07-18 |
Innovative Cellular Therapeutics Inc. |
Modified cell expansion and uses thereof
|
|
CR20200539A
(es)
|
2018-04-10 |
2021-07-01 |
Kite Pharma Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
|
WO2019241688A1
(en)
|
2018-06-14 |
2019-12-19 |
Bluebird Bio, Inc. |
Cd79b chimeric antigen receptors
|
|
CN112368021B
(zh)
|
2018-06-14 |
2025-02-21 |
2赛文缇生物公司 |
Cd79a嵌合抗原受体
|
|
US20210393692A1
(en)
|
2018-11-13 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
WO2020123933A1
(en)
*
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123947A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
EP3714941A1
(en)
|
2019-03-27 |
2020-09-30 |
Medigene Immunotherapies GmbH |
Mage-a4 tcrs
|
|
CN114040926B
(zh)
|
2019-05-04 |
2025-07-29 |
印希比生物科学有限公司 |
结合cd123的多肽及其用途
|
|
EP3966245A1
(en)
|
2019-05-04 |
2022-03-16 |
Inhibrx, Inc. |
Cd33-binding polypeptides and uses thereof
|
|
KR20220004751A
(ko)
|
2019-05-04 |
2022-01-11 |
인히브릭스, 인크. |
CLEC12a 결합 폴리펩타이드 및 이의 용도
|
|
CN114206928B
(zh)
*
|
2019-05-08 |
2025-08-08 |
印希彼生物科学公司 |
Cd33靶向免疫疗法
|
|
WO2020227475A1
(en)
*
|
2019-05-08 |
2020-11-12 |
Bluebird Bio, Inc. |
Cll-1 targeted immunotherapies
|
|
MX2021015495A
(es)
|
2019-06-14 |
2022-04-18 |
2Seventy Bio Inc |
Composiciones y métodos para tratar cáncer.
|
|
KR20220070501A
(ko)
*
|
2019-09-30 |
2022-05-31 |
2세븐티 바이오, 인코포레이티드 |
이량체화제로 조절된 면역수용체 복합체
|
|
WO2021195503A1
(en)
|
2020-03-27 |
2021-09-30 |
2Seventy Bio, Inc. |
T cell receptors
|
|
EP4136119A4
(en)
|
2020-04-17 |
2024-09-11 |
Regeneron Pharmaceuticals, Inc. |
MODIFIED CCR POLYPEPTIDES AND USES THEREOF
|
|
WO2021260696A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Ramot At Tel-Aviv University Ltd. |
Multi subunit protein modules, cells expressing same and uses thereof
|
|
US20230310604A1
(en)
|
2020-08-25 |
2023-10-05 |
2Seventy Bio, Inc. |
Bcma chimeric antigen receptors
|